These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 5141018)

  • 1. [Effect of aldactone on the dynamics and contractility of the heart].
    Schröder R; Schüren KP; Biamino G; Dennert J; Meyer V; Sadée W
    Verh Dtsch Ges Kreislaufforsch; 1971; 37():438-45. PubMed ID: 5141018
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of the aldosterone-antagonist spironolactone on myocardial contractility.
    Strauer BE
    Arch Int Pharmacodyn Ther; 1973 Jan; 201(1):59-70. PubMed ID: 4717388
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myocardial aspects of aldactone effect].
    Strauer BE
    Verh Dtsch Ges Inn Med; 1972; 78():1063-6. PubMed ID: 4665464
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of G strophantin administered per os on the myocardial contractility in the anesthetized dog. Comparison with digoxin].
    Marchetti G; Merlo L; Miragoli G; Ferrini R; Noseda V
    Boll Soc Ital Biol Sper; 1972 Mar; 48(6):130-3. PubMed ID: 5068836
    [No Abstract]   [Full Text] [Related]  

  • 5. Alteration of digoxin toxicity by 6-hydroxydopamine and soironolactone.
    Anders JC; Crisona FJ; Hamrick ME
    Res Commun Chem Pathol Pharmacol; 1980 Sep; 29(3):459-72. PubMed ID: 7423022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effects of digoxin, desoxycorticosterone and spironolactone on the myocardium of the mammal].
    Bacciarelli C
    Arch Int Pharmacodyn Ther; 1967 Mar; 166(1):150-66. PubMed ID: 6034315
    [No Abstract]   [Full Text] [Related]  

  • 7. Action of diphenylhydantoin on rhythmicity and contractility of cultured embryonic heart cells.
    Kleinfeld M; Schade O; Gruen F
    J Pharmacol Exp Ther; 1969 Nov; 170(1):84-90. PubMed ID: 5351008
    [No Abstract]   [Full Text] [Related]  

  • 8. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
    Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the subcellular distribution of digoxin with the positive inotropic effect.
    Kim ND; Bailey LE; Dresel PE
    J Pharmacol Exp Ther; 1972 May; 181(2):377-85. PubMed ID: 5030678
    [No Abstract]   [Full Text] [Related]  

  • 10. Antagonism of aldosterone in normal subjects by Ro 12-2503 and spironolactone.
    Dux S; Rosenfeld J; Cocco G; Chu D; Gasser DF
    Arzneimittelforschung; 1982; 32(2):164-9. PubMed ID: 7199923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between digoxin and potassium-sparing diuretics.
    Waldorff S; Hansen PB; Egeblad H; Berning J; Buch J; Kjaergård H; Steiness E
    Clin Pharmacol Ther; 1983 Apr; 33(4):418-23. PubMed ID: 6831820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of intracellular depolarization rates and contractility in the dog ventricle in situ: effects of positive and negative inotropic agents.
    Pruett JK; Woods EF
    J Pharmacol Exp Ther; 1967 Jul; 157(1):1-7. PubMed ID: 6029486
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of aldosterone on isolated human penile corpus cavernosum tissue.
    Muguruma H; Kawanishi Y; Sugiyama H; Kagawa J; Tanimoto S; Yamanaka M; Kojima K; Anzai H; Numata A; Kishimoto T; Kanayama HO
    BJU Int; 2008 Aug; 102(4):500-3. PubMed ID: 18294301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):987-8. PubMed ID: 10488324
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure of the aldosterone antagonist spironolactone to inhibit myocardial hypertrophy produced by experimental hyperthyroidism and accompanied by "apparent" digoxin immunoreactivity in the blood.
    Schreiber V; Stĕpan J; Kölbel F; Pribyl T; Jahodová J; Kubová V
    Physiol Bohemoslov; 1980; 29(6):577-9. PubMed ID: 6451886
    [No Abstract]   [Full Text] [Related]  

  • 16. Working heart function in diabetes is not improved by spironolactone treatment.
    Verma S; Yuen VG; Badiwala M; Anderson TJ; McNeill JH
    Can J Physiol Pharmacol; 2003 May; 81(5):493-6. PubMed ID: 12774856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
    Liang YH; Wang JM; Zhou Y; Jiang XJ; Jiang H; Huang CX
    Life Sci; 2004 Aug; 75(15):1871-8. PubMed ID: 15302230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among contraction, drug binding and positive inotropic action of digoxin.
    Roth-Schechter BF; Okita GT; Anderson D; Richardson F
    J Pharmacol Exp Ther; 1970 Feb; 171(2):249-55. PubMed ID: 5459061
    [No Abstract]   [Full Text] [Related]  

  • 19. [The significance of aldosterone in chronic heart failure: the RALES study].
    Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
    Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone antagonists in congestive heart failure.
    Soberman J; Chafin CC; Weber KT
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.